التفاصيل البيبلوغرافية
| العنوان: |
A Time-Trend Economic Analysis of Cancer Drug Trials. |
| المؤلفون: |
Cressman, Sonya, Browman, George P., Hoch, Jeffrey S., Kovacic, Laurel, Peacock, Stuart J. |
| المصدر: |
Oncologist; 2015, Vol. 20 Issue 7, p729-736, 8p, 1 Chart, 1 Graph |
| مصطلحات موضوعية: |
CLINICAL trials, ANTINEOPLASTIC agents, COST effectiveness, TIME, TUMORS, HEALTH insurance reimbursement, DRUG approval, CONTINUING education units, DESCRIPTIVE statistics, ECONOMICS |
| مصطلحات جغرافية: |
AUSTRALIA, CANADA, UNITED Kingdom, UNITED States |
| الشركة/الكيان: |
UNITED States. Food & Drug Administration |
| مستخلص: |
Background. Scientific advances have led to the discovery of novel treatments with high prices. The cost to publicly fund high-cost drugs may threaten the sustainability of drug budgets in different health care systems. In oncology, there are concerns that health-benefit gains are diminishing over time and that the economic evidence to support funding decisions is too limited. Methods. To assess the additional costs and benefits gained from oncology drugs over time, we used treatment protocols and efficacy results from U.S. Food and Drug Administration records to calculate cost-effectiveness ratios for drugs approved to treat first- and second-line metastatic or advanced breast, colorectal, and non-small cell lung cancer during the years 1994-2013. We assessed reimbursement recommendations reached by health technology assessment agencies in the U.K., Australia, and Canada. Results. Cost-effectiveness ratios were calculated for 50 drugs approved by the U.S. regulator. The more recent approvals were often based on surrogate efficacy outcomes and had extremely high costs, often triple the costs of drugs approved in previous years. Over time, the effectiveness gains have increased for some cancer indications; however, for other indications (non-small cell lung and second-line colorectal cancer), the magnitude of gains in effectiveness decreased. Reimbursement recommendations for drugs with the highest cost-effectiveness ratios were the most inconsistent. Conclusion. Evaluation of the clinical benefits that oncology drugs offer as a function of their cost has become highly complex, and for some clinical indications, health benefits are diminishing over time. There is an urgent need for better economic evidence from oncology drug trials and systematic processes to inform funding decisions. [ABSTRACT FROM AUTHOR] |
|
Copyright of Oncologist is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder